These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE; Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017 [TBL] [Abstract][Full Text] [Related]
10. Triple Therapy for Cystic Fibrosis with a Phe508del CFTR Mutation. McGarry ME N Engl J Med; 2020 Feb; 382(7):684. PubMed ID: 32053310 [No Abstract] [Full Text] [Related]
11. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results. Murer C; Huber LC; Kurowski T; Hirt A; Robinson CA; Bürgi U; Benden C Swiss Med Wkly; 2018; 148():w14593. PubMed ID: 29451946 [TBL] [Abstract][Full Text] [Related]
12. Prolonged co-treatment with HGF sustains epithelial integrity and improves pharmacological rescue of Phe508del-CFTR. Matos AM; Gomes-Duarte A; Faria M; Barros P; Jordan P; Amaral MD; Matos P Sci Rep; 2018 Aug; 8(1):13026. PubMed ID: 30158635 [TBL] [Abstract][Full Text] [Related]
13. Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation. Dilokthornsakul P; Patidar M; Campbell JD Value Health; 2017 Dec; 20(10):1329-1335. PubMed ID: 29241892 [TBL] [Abstract][Full Text] [Related]
14. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy. Connett GJ Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974 [TBL] [Abstract][Full Text] [Related]
15. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419 [TBL] [Abstract][Full Text] [Related]
16. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
17. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation. Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700 [TBL] [Abstract][Full Text] [Related]
19. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. Taylor-Cousar JL; Munck A; McKone EF; van der Ent CK; Moeller A; Simard C; Wang LT; Ingenito EP; McKee C; Lu Y; Lekstrom-Himes J; Elborn JS N Engl J Med; 2017 Nov; 377(21):2013-2023. PubMed ID: 29099344 [TBL] [Abstract][Full Text] [Related]
20. Identification and selection of healthy spermatozoa in heterozygous carriers of the Phe508del-variant of the CFTR-gene in assisted reproduction. De Geyter J; Gallati-Kraemer S; Zhang H; De Geyter C Sci Rep; 2022 Feb; 12(1):1866. PubMed ID: 35115637 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]